FeNO leadership Position FeNO by NIOX USA as the leading, non-invasive FeNO testing solution for asthma diagnosis and management, emphasizing its use in diverse settings from clinics to hospitals to primary care to capture opportunities across care continuum.

Market expansion Leverage the company’s global leadership in FeNO testing to target respiratory care networks, ambulatory clinics, and EHR-enabled practices that value objective asthma biomarkers, highlighting potential upsell of training, support, and device deployments.

Healthcare partnerships Highlight current and past collaborations (AHSN Network, Vitalograph partnership) to propose joint programs, educational initiatives, and pilot deployments with health systems and professional societies to expand adoption.

Clinical validation Use the robust body of validation and clinical utility cited in referenced studies to support ROI for clinics and hospital systems, tying FeNO measurement to improved diagnostic accuracy, personalized treatment, and potential reduction in exacerbations.

Growth signals Monitor financial and funding signals such as revenue indicators and strategic leadership changes to time outbound outreach for enterprise deals, distributor channels, and regional expansions that align with sales cycles.